Enliven Therapeutics Reports Clinical Breakthrough in Therapy-Resistant Leukemia

Enliven Therapeutics is a clinically oriented biopharmaceutical company based in Boulder, Colorado, focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The focus is on precision oncology approaches using highly selective kinase inhibitors that aim to overcome resistance mechanisms and improve efficacy in hard-to-treat tumors. Among the leading drug candidates is ELVN-001, an active inhibitor for the treatment of chronic myeloid leukemia. The company is also pursuing substances such as ELVN-002...